Impact News +++ Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a... (GlobeNewswire EN) +++ CARDIFF ONCOLOGY Aktie +4,53%

MESOBLAST Aktie

>MESOBLAST Aktienkurs

1.39 EUR -2.6% (TradegateBSX)

Ask: 1.39 EUR / 47533 Stück

Bid: 1.37 EUR / 1504 Stück

Tagesumsatz: 12527 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

MESOBLAST Aktie über LYNX handeln

Intraday

1 Jahr

>MESOBLAST Performance

1 Woche: +11,2%

1 Monat: +14,9%

3 Monate: -9,2%

6 Monate: -1,4%

1 Jahr: +50,3%

laufendes Jahr: -7,6%

>MESOBLAST Aktie

Name:

MESOBLAST LTD.

Land:

Australien

Sektor:

Gesundheit

ISIN/ Wkn:

AU000000MSB8 / A0DNPW

Symbol/ Ticker:

LWB (Frankfurt)

Kürzel:

FRA:LWB, ETR:LWB, LWB:GR

Index:

Webseite:

https://www.mesoblast.com..

Profil:

Mesoblast Limited is a biotechnology company specializing in the development of allogeneic, or off-the-shelf, cellular medicines intended for the treatment of severe and life-threatening inflammatory conditions. Leveraging a proprietary technology pl..
>Volltext..

Marktkapitalisierung:

1771.54 Mio. EUR

Unternehmenswert:

1775.95 Mio. EUR

Umsatz:

57 Mio. EUR

EBITDA:

-56.86 Mio. EUR

Nettogewinn:

-83.23 Mio. EUR

Gewinn je Aktie:

-0.06 EUR

Schulden:

114.95 Mio. EUR

Liquide Mittel:

110.55 Mio. EUR

Operativer Cashflow:

-62.38 Mio. EUR

Bargeldquote:

1.01

Umsatzwachstum:

1011.51%

Gewinnwachstum:

10.99%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

MESOBLAST

Letzte Datenerhebung:

18.04.26

>MESOBLAST Kennzahlen

Aktien/ Unternehmen:

Aktien: 1292.82 Mio. St.

Frei handelbar: 66.6%

Leerverk. Aktien: -

Rückkaufquote: -8.59%

Mitarbeiter: 81

Umsatz/Mitarb.: 0.18 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 82.92%

Bewertung:

KGV: -

KGV lG: -

KUV: 27.5

KBV: 3.62

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 48.65%

Gewinnmarge: -146.03%

Operative Marge: -113.08%

Managementeffizenz:

Gesamtkaprendite: -13.17%

Eigenkaprendite: -18.27%

>MESOBLAST Peer Group

Gesundheit, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten, Herz-Kreislauf- Behandlung/ Kardiologie

>MESOBLAST Chart & Kurs - Tradegate

>MESOBLAST News

16.04.26 - 04:48	Down almost 20% this year, how high could Mesoblast shares go? (Fool)
	The forward pipeline is looking promising. The post Down almost 20% this year, how high could Mesoblast shares go? appeared first on The Motley Fool Australia....

15.04.26 - 16:27	Mesoblast gains on licensing deal for CAR technology platform (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

15.04.26 - 07:48	Why are Mesoblast shares jumping 8% today? (Fool)
	The biotech star has announced an exciting acquisition on Wednesday. The post Why are Mesoblast shares jumping 8% today? appeared first on The Motley Fool Australia....

15.04.26 - 06:24	Why Evolution Mining, Mesoblast, Nufarm, and Virgin Australia shares are storming higher today (Fool)
	These shares are having a good session on hump day. But why? The post Why Evolution Mining, Mesoblast, Nufarm, and Virgin Australia shares are storming higher today appeared first on The Motley Fool Australia....

15.04.26 - 02:12

Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products (GlobeNewswire EN)

NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has acquired an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform for precision-enhanced augmentation of therapeutic mesenchymal lineage stromal cell (MSC) products. Mesoblast plans to incorporate the engineered CARs to further boost effectiveness of Mesoblast's products, with the goal of enhancing the target specificity and augmenting inherent properties of immunomodulation and tissue regeneration....

10.04.26 - 22:12	Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION (GlobeNewswire EN)
	Working with Parent Project Muscular Dystrophy and the Duchenne Registry on patient identification and trial awareness efforts ...

10.04.26 - 06:12	Why Amaero, Mesoblast, Telix, and Tivan shares are charging higher today (Fool)
	These shares are ending the week on a high. But why? The post Why Amaero, Mesoblast, Telix, and Tivan shares are charging higher today appeared first on The Motley Fool Australia....

08.04.26 - 15:12	Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation (GlobeNewswire EN)
	Mesoblast outlines commercial strategy to double net revenues as Ryoncil® approaches US$100M net revenue milestone since launch last year...

08.04.26 - 13:33	Mesoblast gains as FDA clears study to test Ryoncil in Duchenne (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

08.04.26 - 05:36	Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy (GlobeNewswire EN)
	Partnering with Parent Project Muscular Dystrophy to ensure timely access to the trial for eligible patients...

07.04.26 - 17:18	Mesoblast drops after Ryoncil sales data for March quarter (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

07.04.26 - 08:12	Why Challenger, Lotus Resources, Mesoblast, and Wildcat shares are falling today (Fool)
	These shares are starting the week in the red. But why? The post Why Challenger, Lotus Resources, Mesoblast, and Wildcat shares are falling today appeared first on The Motley Fool Australia....

07.04.26 - 04:36	Mesoblast shares are back in the red on Tuesday. Here′s why (Fool)
	Mesoblast shares slip despite another strong quarterly sales update from Ryoncil. The post Mesoblast shares are back in the red on Tuesday. Here's why appeared first on The Motley Fool Australia....

07.04.26 - 03:00	Mesoblast shares: Ryoncil® underpins strong earnings growth (Fool)
	Mesoblast shares are in focus as Ryoncil® delivers nearly US$100m in sales since launch, fueling future growth initiatives. The post Mesoblast shares: Ryoncil® underpins strong earnings growth appeared first on The Motley Fool Australia....

18.03.26 - 00:24

Mesoblast to Host R&D Day on April 8, 2026 (GlobeNewswire EN)

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host its inaugural R&D Day on Wednesday, April 8, 2026 in New York City. The event will be webcast live from 8:00am to 11:00am EST and will include presentations from Mesoblast's senior leadership team and from key opinion leaders....

12.03.26 - 00:24

Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast (GlobeNewswire EN)

NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the appointment of Teresa Montagut MD, PhD in the newly established position of Head of Clinical Development and Medical Affairs reporting to the Chief Medical Officer Dr. Eric Rose. In this role, Teresa will lead Mesoblast's medical affairs organization, fostering clinical collaborations and spearheading investigator-initiated trials, enhancing clinical and medical communications, and engaging with healthcare professionals. She will play a critical role in unlocking the value of Mesoblast's cell therapy programs in new pediatric and adult inflammatory conditions in partnership with investigators and key opinion leaders....

27.02.26 - 09:33	Mesoblast misses H1 estimates (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

27.02.26 - 01:48	What′s going on with Mesoblast shares today? (Fool)
	This biotech was up almost 9% before sinking into the red. The post What's going on with Mesoblast shares today? appeared first on The Motley Fool Australia....

27.02.26 - 00:24	Mesoblast shares: Revenue surges on Ryoncil® US launch in H1 FY2026 (Fool)
	Mesoblast posts strong H1 FY2026 results on the back of Ryoncil®'s US launch and robust revenue growth. The post Mesoblast shares: Revenue surges on Ryoncil® US launch in H1 FY2026 appeared first on The Motley Fool Australia....

20.02.26 - 13:03	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire EN)
	NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the half year ended December 31, 2025....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: In Fährden ist das höchste Gut die Kühnheit. - In rebus dubiis plurimi est audacia. - Publilius Syrus

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram